Renflexis®
Understanding Renflexis®
Renflexis® (infliximab-abda) is a biosimilar to Remicade® (infliximab), designed to treat various autoimmune diseases by inhibiting tumor necrosis factor-alpha (TNF-α), a substance in the body that causes inflammation.
How Renflexis® Works:
TNF-α Inhibition: Renflexis® binds to TNF-α, blocking its interaction with TNF receptors on cell surfaces, thereby reducing inflammation and altering the immune response associated with various autoimmune conditions.
FDA Approval:
Renflexis® was approved by the U.S. Food and Drug Administration (FDA) on April 21, 2017, for multiple indications, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
For more information, please visit the Renflexis® patient website and consult your healthcare provider to determine if Renflexis® is the right treatment option for you.
Referral Form: |
MANUFACTURER: Samsung Bioepis |
CLASS: Infliximab injection products are in a class of medications called tumor necrosis factor-alpha (TNF-alpha) inhibitors. |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Every eight weeks after an initial induction phase of doses given at weeks zero, two, and six |
Length of infusion: About two hours |
FOR MORE INFORMATION: |
Related drugs
